 "Dr Reddy's Laboratories working on enhancing Covid-19 portfolio")
Dr Reddy’s Laboratories (DRL) is working on several product extensions as well as market expansions for its Covid products portfolio. For example, it is working on bringing in a 1 ml liquid intravenous injectable version of Gilead’s remdesivir, a drug widely used for Covid patients with moderate to severe symptoms.
Similarly, for its oral antiviral drug favipiravir, which it sells under an agreement with Japanese innovator FujiFilm, it is looking to expand markets beyond India, the company said.
As for MSD’s drug Molnupiravir, which is currently undergoing clinical trial in India, the company said it has already shared interim data with the drug regulator.
DRL is also trying to have label expansion for mild patients for the 2-DG or 2-Deoxy-d-Glucose that it developed with the Institute of Nuclear Medicine & Allied Sciences, a Defence Research and Development Organisation arm.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%